Abstract
Introduction

▼
Obesity is now well recognized as being associated with a state of systemic low-grade infl ammation [ 1 , 2 ] . During a situation of energy imbalance (increased caloric intake or diminished expenditure), adipocytes serve as energy stores for the circulating excess nutrients. This increased storage is accompanied by secretion of multiple adipokines (adipocyte-derived hormones) that can aff ect whole-body metabolism as well as recruit immune cells to adipose tissue [ 3 , 4 ] . Immune infi ltration into adipose tissue has been linked to a plethora of complications including insulin resistance, cardiovascular diseases, metabolic syndrome and type-2 diabetes [ 5 ] . Acylation stimulating protein (ASP, aka C3adesArg) is one such adipokine that correlates with various metabolic and hormonal disturbances. Plasma levels are increased with insulin resistance, cardiovascular disease, metabolic syndrome, type 2 diabetes and polycystic ovary disease, even in the absence of obesity. Dietary lipoproteins (in the form of chylomicrons), as well as insulin, increase C3 and ASP production in vivo, and plasma ASP correlates with fat clearance in vivo [ 6 , 7 ] . On the other hand, plasma ASP concentrations diminish following diet, exercise or bariatric surgery [ 8 , 9 ] . ASP is derived from complement component C3 which, when activated, is cleaved to produce the anaphylatoxins C3a and C3b (which can then proceed to initiate the alternative complement immune pathway). In circulation, C3a rapidly undergoes C-terminal cleavage via carboxypeptidase B to produce C3adesArg (ASP) [ 8 ] . The amount of C3adesArg/ASP generated will depend on the local C3 concentration as well as the rate of enzymatic conversion of C3 to ASP. Adipose tissue C3 mRNA increases in obesity and correlates with body mass index (BMI), however, the proportion of ASP relative to C3 in plasma is low ( < 0.5 %), suggesting that there is stringent regulation of conversion from C3 to ASP [ 10 ] . ASP has been shown to act through a 7-transmembrane receptor (C5L2) to stimulate fatty acid uptake and esterifi cation as well as glucose transport into adipocytes while decreasing lipolysis via inhibition of hormone-sensitive lipase. These eff ects are independent and additive to those of insulin [ 8 ] . C5L2 receptor is present in adipocytes, but also in muscle, brain, spleen, liver and immune cells [ 11 ] . In addition to lipogenic eff ects, recent studies have shown that ASP can increase adipocyte production of other adipokines as well as infl ammatory factors, including macrophage chemoattractant protein-1 (MCP-1) and KC (murine ortholog of IL-8). These pro-infl ammatory factors are partly responsible for the recruitment of macrophages into adipose tissue, thus initiating interaction between adipose and immune cells. Based on these results, we set out to identify other infl ammatory and metabolic hormones that would aff ect ASP production using a 3T3-L1 cell model.
Materials and Methods
▼
Materials
Reagents were obtained as follows: leptin, TNFα, IL-10, adiponectin, KC and RANTES were purchased from ProSpec-Tany TechnoGene Ltd (Rehovot, Israel), LPS from Sigma-Aldrich (Oakville, ON, Canada). Apelin and Visfatin were obtained from Phoenix Pharmaceuticals Inc (Burlingame, CA, USA). Omentin was obtained from Enzo Life Sciences Inc in Farmingdale, NY, USA and C5a was acquired at VWR in Mississauga, ON, Canada. All tissue culture reagents, including Dulbeccos's modifi ed Eagle's medium/F-12 (DMEM/F12), phosphate buff ered saline (PBS), fetal bovine serum (FBS), trypsin and tissue culture supplies were from Gibco (Burlington, ON, Canada). Triglyceride (TG) mass was measured using an enzymatic colorimetric assay (Roche Diagnostic, Indianapolis, IN, USA).
Cell culture and 3T3-L1 diff erentiation
3T3-L1 preadipocytes and J774 macrophages were purchased from the American Type Culture Collection (Manassas, VA, USA). Cells were cultured and diff erentiated as described previously [ 6 ] . Briefl y; Preadipocytes (3T3-L1) were plated in 24-well culture plates ( ≈ 3 × 10 4 cells/welL) and diff erentiated with medium containing 10 μg/ml insulin, 1 μM dexamethasone and 500 μM isobutylmethylxanthine (IBMX). Diff erentiated cells, at least 90 % of which showed an adipocyte phenotype by accumulation of lipid droplets (as determined by microscopic evaluation), were used on days 8-12 after initiation of diff erentiation. J774 macrophages were plated in 12-well culture plates ( ≈ 1 × 10 5 cells/ well; trypan blue exclusion) and used within 2-3 days.
Direct and indirect co-culture of adipocytes and macrophages
Direct coculture was performed by adding J774 macrophages ( ≈ 1 × 10 5 viable cells/well; trypan blue exclusion) into 12-well culture plates containing diff erentiated 3T3-L1 adipocytes ( ≈ 1 × 10 5 cells/well). The same numbers of J774 and 3T3-L1 cells were also plated separately in diff erent wells for comparison. Adipocytes and macrophages were in contact in fresh serumfree medium for 2 h before addition of any treatments.
Cell treatments
Adipocytes, macrophages and co-cultured cells were incubated for 2 h in serum-free medium (DMEM/F12) prior to stimulation at various physiological concentrations with the treatments as indicated. All of the treatments were conducted in serum free medium. After 24 h of treatment, the culture supernatants were collected and stored at − 80 °C until analysis.
Medium ASP and C3 determination
Mouse ASP (C3a) ELISA reagents were from BD Pharmingen (Franklin Lakes, NJ, USA). ASP was measured using a sandwich ELISA as described previously [ 6 ] . Note, the antibody used in this ELISA is specifi c for a neoepitope exposed in mouse C3a and its desArginated form (ASP), but does not cross-react with the native protein C3. A mouse complement C3 ELISA kit (Kamiya Biomedical, Seattle, WA, USA) was used to measure total C3, including native and breakdown products, and was used according to the manufacturer's instructions with calculation by linear regression against a standard curve. TG mass was measured using an enzymatic colorimetric assay (Roche Diagnostics, Indianapolis, IN, USA).
Statistical analyses
Results are presented as mean ± SEM. Each experiment was performed at least 3 times, with individual triplicate analyses in each experiment (n = 9). ASP and C3 production were quantifi ed in each experiment, normalized to cell TG mass (nmol/well), and reported relative to the untreated control (CTL = 100 %), which was cells incubated in serum-free medium alone. The proportion of C3 converted to ASP is calculated as % ASP/C3 (ng/ng).
Comparison between 2 groups was determined by Student's t -test and comparisons amongst several groups were performed by 1-way ANOVA followed by Newman-Keuls or Dunnett's multiple comparison post-test using Prism software (Graphpad Software). Statistical signifi cance was set at P < 0.05, where NS indicates not signifi cant relative to the indicated control. . 1a ; 100 ng/mL, 151 %, P < 0.01 and 1 000 ng/mL, 132 %, P < 0.05). C3 secretion increased slightly at 10 ng/ml and 1 000 ng/ml of leptin treatment but was only signifi cantly increased at 100 ng/ml ( • ▶ Fig. 2a ; 165 %, P < 0.05). The ratio of ASP to C3, which refl ects the conversion rate of C3 to ASP was constant at all leptin concentrations used (data not shown). Both HMW adiponectin (HMW previously defi ned above) adiponectin and globular (gAcrp) adiponectin were used to treat diff erentiated 3T3-L1 adipocytes. The highest concentration of HMW adiponectin (5 ug/ml) increased ASP production and C3 secretion in 3T3-L1 adipocytes ( • ▶ Fig. 1b , 2b ; 153 %, 152 %, , KC e in serum-free media for 24 h. As well, diff erentiated adipocytes were treated with macrophage-conditioned media (CM) or cultured directly with macrophages (co-culture) for the same time period f . ASP was subsequently measured, normalized to cell TG mass (nmol/well) and reported relative to the untreated control (CTL = 100 %), which were cells incubated in serum-free medium alone. Results are presented as average ± SEM (n = 9). Signifi cant changes were evaluated by ANOVA with post-hoc test as described in methods. , KC e in serum-free media for 24 h. As well, diff erentiated adipocytes were treated with macrophage-conditioned media or cultured directly with macrophages (co-culture) for the same time period f . C3 was subsequently measured, normalized to cell TG mass (nmol/well) and reported relative to the untreated control (CTL = 100 %), which were cells incubated in serum-free medium alone. Results are presented as average ± SEM (n = 9). Signifi cant changes were evaluated by ANOVA with post-hoc test as described in methods. 0.2 ug/mL and 1 ug/mL). The conversion of C3 to ASP ( %ASP/C3) did not change (data not shown). These results suggest that fulllength adiponectin and leptin could stimulate ASP production in adipocytes by increasing precursor C3 production rather than conversion.
Results
▼
P
Eff ects of novel adipokines apelin, omentin and visfatin on ASP and C3 secretion in 3T3-L1 adipocytes
ASP production and C3 secretion subsequent to treatment with apelin, omentin and visfatin were also evaluated. Both concentrations (1 ng/mL, 10 ng/mL) of omentin decreased ASP production but only the highest concentration of apelin and visfatin (10 ng/ml) signifi cantly decreased ASP production in 3T3-L1 adipocytes ( • ▶ Fig. 1c ; P < 0.05, P < 0.01, respectively). C3 secretion did not signifi cantly change at any treatment concentration with the adipokines tested ( P NS; • ▶ Fig. 2c ). The ratio of ASP to C3
was also decreased at both concentrations of apelin and omentin as well as at the highest concentration of visfatin (10`ng/ml) ( • ▶ Fig. 3a ; P < 0.05). The results suggest that apelin, omentin and visfatin could inhibit ASP production in adipocytes by decreasing the rate of C3 conversion.
Eff ects of infl ammatory factors IL-10, TNF-α and lipopolysaccharide (LPS) on ASP production and C3 secretion in 3T3-L1 adipocytes ASP and C3 secretion stimulated by IL-10, TNF-α and LPS are also shown here. Only the highest concentrations of IL-10 (25 pg/ml) and TNF-α (1 000 pg/ml) increased ASP production in 3T3-L1 adipocytes ( • ▶ Fig. 1d ; 190 %, 134 %, P < 0.05, respectively). With LPS treatment, all concentrations strongly stimulated ASP production ( • ▶ Fig. 1d ; 0.01 ng/mL, 220 %, P < 0.001; 1 ng/mL, 318 %, P < 0.001; 100 ng/mL, 188 %, P < 0.01).
Interestingly, IL-10 treatment decreased C3 production at lower concentrations ( • ▶ Fig. 2d ; 1 pg/mL, P < 0.05; 5 pg/ml, P < 0.01) but there was no change in C3 production at the highest concentration (25 pg/ml). For TNF-α and LPS treatments, changes in C3 secretion followed the same direction as the ASP changes: the highest concentration of TNF-α increased C3 secretion ( • ▶ Fig. 2d ; 210 %, P < 0.05) while all concentrations of LPS strongly stimulated C3 secretion ( • ▶ Fig. 2d ; 415 %, P < 0.001; 423 %, P < 0.001; 215 %, P < 0.01).
The ratio of ASP to C3 is signifi cantly increased for the highest IL-10 concentration, with a concentration dependent eff ect ( • ▶ Fig. 3b ; P < 0.001), suggesting that relative ASP production changed less at lower IL-10 levels, but is increased with a supraphysiological concentration. With LPS treatment, both ASP and C3 increased, and the relative ASP/C3 ratio was unchanged (data not shown). Although overall, TNF-α stimulated both C3 and ASP, the ratio of ASP/C3 varied, with an increase in ASP/C3 at the lowest concentration of TNF-α (10 pg/ml), and a relative decrease at the highest concentration (data not shown).
Eff ects of infl ammatory factors RANTES, C5a and KC on ASP and C3 secretion in 3T3-L1 adipocytes
In contrast to the stimulatory eff ects of IL-10, TNFα and LPS, there was a decrease in ASP production when RANTES and C5a were used. All concentrations of RANTES decreased ASP produc- Fig. 1e , 2e ; P NS ,). As the changes in ASP and C3 paralleled each other, the ratio of ASP/C3 was unchanged for RANTES, C5a or KC treatments (data not shown). These results suggest that RANTES and C5a may both inhibit ASP production in adipocytes by decreasing precursor C3 secretion.
Eff ects of direct co-culture with macrophages and macrophage-conditioned media on ASP and C3 secretion in 3T3-L1 adipocytes
We evaluated the eff ects of macrophages directly on ASP and C3 in 3T3-L1 adipocytes. Macrophage conditioned media (CM) was collected after overnight treatment of J774 in serum-free media. No ASP or C3 was detectable in the conditioned-media. Further, conditioned-media had no eff ect on secretion of C3, production of ASP or the ASP/C3 ratio in 3T3-L1 adipocytes ( • ▶ Fig. 1f , 2f , 3c; P NS ). However, direct co-culture of adipocytes with J774 cells enhanced secretion of C3 and production of ASP in adipocytes.
Moreover, the relative increase in ASP ( • ▶ Fig. 1f ; 272 %, P < 0.001) was much higher than that of C3 secretion ( • ▶ Fig. 2f ; 167 %, P < 0.001), which refl ects a higher conversion of C3 to ASP. These results suggest that increased ASP levels are a result of increased precursor levels as well as increased rates of conversion ( • ▶ Fig. 3c ; 162 %, P < 0.05).
Discussion
▼
Here, the eff ects of various physiological concentrations of cytokines and hormones involved in infl ammatory processes or metabolic disturbances on the production of ASP and its precursor (complement C3) were tested in diff erentiated adipocytes. Fig. 3 Eff ects of treatments on ratio of C3 to ASP conversion. 3T3-L1 adipocytes were diff erentiated, then treated with the indicated concentrations of apelin, omentin and visfatin a , IL-10 b and with macrophage-conditioned media (CM) or cultured directly (co-culture) with macrophages c for 24 h. ASP and complement C3 were subsequently measured and the ratio of ASP to C3 was calculated as ng/ng, where the untreated control was set as 100 % for comparison. Results are presented as average ± SEM (n = 9). Signifi cant changes were evaluated by ANOVA with post-hoc test as described in methods.
Furthermore, we measured ASP production in a cell model mimicking an obese environment: co-culture of adipocytes with macrophages, or treatment with macrophage conditioned media. These novel results indicate that various metabolic hormones and infl ammatory factors have varying eff ects on ASP and C3 production in 3T3-L1 adipocytes. The overall pattern was that infl ammatory factors stimulated ASP secretion in 3T3-L1 adipocytes while most of the insulin sensitizing hormones decreased its secretion (with the exception of adiponectin), and the implications of this are discussed below both, fi rst for the individual factors in relationship to physiological data, as well as overall. However, there are some limitations in this study that should be acknowledged. First, 3T3-L1 adipocytes and J774 macrophages are murine cell lines, and do not represent the heterogeneity which is found in adipocytes derived from humans. The co-culture and conditioned media approaches were used to mimic the situation in adipose tissue from obese subjects, where macrophage infi ltration is present. Nonetheless, this still represents an imperfect scenario, and does not capture the adipose tissue infl ammation observed in obese subjects in relation to heterogeneity in adipocyte size, macrophage phenotype and even gender and age. Further, we only detected ASP and C3 secretion for 24 h of treatment and long-term eff ects of these treatments have yet to be elucidated.
The eff ects of the metabolic hormones apelin, visfatin and omentin on ASP and C3 production
Apelin is mainly produced and secreted by adipocytes, and stimulates glucose uptake through the PI3K/Akt pathway, improving insulin resistance in 3T3-L1 adipocytes [ 12 ] . Visfatin, mainly produced by lymphocytes, decreases insulin resistance: administration in mice decreases blood glucose levels, whereas mice lacking one allele have increased plasma glucose [ 13 ] . Omentin, an adipokine preferentially produced by visceral adipose tissue, has insulin-sensitizing eff ects, and circulating levels are decreased in insulin-resistant states [ 14 ] . Altogether, these adipokines exert benefi cial eff ects in metabolic syndrome and all have similar eff ects of diminishing ASP production via lowering C3 conversion rates (with no eff ect on C3 secretion).
The eff ects of anti-infl ammatory markers on ASP and C3 production
Many studies demonstrate that adiponectin has direct anti-diabetic, anti-atherogenic and anti-infl ammatory functions [ 15 , 16 ] . Adiponectin can exist as a full-length or a smaller, globular fragment. While most plasma adiponectin appears to be in the fulllength isoform, forming multimers as 3 diff erent oligomeric complexes, high molecular weight (HMW), middle molecular weight (MMW) and low molecular weight (LMW), a small amount of globular adiponectin (gAcrp) can be detected in human plasma. Although adiponectin improves insulin resistance, similar to the adipokines mentioned above, by contrast it did not have the same eff ects on ASP and C3 production. Interestingly, in obese subjects, plasma adiponectin decreases, while other insulin sensitizing hormones such as apelin are increased in obese subjects. An alternate link between adiponectin and ASP may be found in the study by Peake et al., which showed that adiponectin was bound by the globular domain of the A chain of collagenase-digested complement C1q, and C1q binding induced deposition of C4 and C3 through activation of the classical complement pathway [ 17 ] . As a member of the pattern-recognition family of defense collagens, adiponectin binds targeted molecules and activates complement. Thus, it could directly stimulate C3 production and cleavage to increase ASP production (as demonstrated here). Interleukin (IL)-10 is a major anti-infl ammatory cytokine that plays a crucial role in the regulation of the immune system. High levels of circulating IL-10 are associated with obesity and metabolic syndrome [ 18 , 19 ] . Moreover IL-10 levels decrease following weight loss [ 20 ] . We found that IL-10 could directly inhibit C3 secretion in adipocytes. However, ASP levels do not decrease (relative to control), probably due to an increase in C3 conversion to ASP. This is also consistent with in vivo studies, which have shown that both ASP and IL-10 are increased in obesity and infectious diseases, although the underlying mechanisms are still unclear.
The eff ects of pro-infl ammatory markers on ASP and C3 production
Leptin is one of the more prominently studied adipokines, inhibiting food consumption and stimulating energy expenditure [ 21 ] . Moreover leptin also has a pro-infl ammatory eff ect [ 22 ] . In the present study, a high concentration of leptin increased ASP and C3 secretion, which is consistent with previous in vivo studies where subjects with obesity, diabetes and cardiovascular disease have both increased leptin and ASP [ 8 , 23 ] . Tumour necrosis factor-alpha (TNF-α) is a proinfl ammatory cytokine secreted by various cells including monocytes, macrophages and adipocytes [ 24 , 25 ] with roles in acute phase response, lipid metabolism and adipocyte function [ 26 -28 ] . Plasma TNF-α levels and expression of TNF-α in adipose tissue are increased in obesity and correlate with insulin resistance [ 29 ] . In this study, we found that the highest concentration of TNF-α (1 000 pg/ml) increased C3 and ASP secretion, although the ASP increase was not proportional to the C3 increase. Lipopolysaccharide (LPS) is a strong inducer of infl ammation and was shown to trigger secretion of immunomodulatory molecules such as TNF-α, IL-6 and MCP-1 in diff erentiated 3T3-L1 adipocytes via toll-like receptor activation [ 30 ] . LPS administration, a widely used experimental model of infection and infl ammation, also induces hyperglycemia and insulin resistance in mice [ 31 , 32 ] . Physiologically, circulating LPS increases in Type 2 diabetes, and is preferentially associated with postprandial chylomicrons [ 30 ] , which, in turn, increase C3 secretion and C3 conversion to ASP [ 33 ] . The present study shows that ASP production and C3 secretion were increased 2-4 fold, even at very low LPS concentrations (0.01 ng/ml).
The eff ects of chemokines on ASP and C3 production
Chemokines produced by fat, including C5a, IL-8, MCP-1, and RANTES are often regulated by adipokines [ 34 ] . Links between RANTES and C3 have been described previously: serum RANTES is increased in systemic lupus erythematosus and correlates with C3 levels [ 35 ] ; C3 and C5 defi cient mice have decreased RANTES and MCP1, and treatment with C3a or C5a caused upregulation of IL-8, IL-1ß, and RANTES mRNA in a time-and dosedependent manner in human umbilical cord endothelial cells [ 36 ] . These results suggest that C3 could contribute to the positive regulation of RANTES production. C3 activation also leads to complement cascade responses to produce the chemoattractants C3a and C5a. We speculate that there may exist a feedback regulation eff ect of RANTES and C5a on adipocyte C3 production. Lower levels of C3 would then be refl ected in lower levels of This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
circulating ASP, as shown here. An additional point that should be highlighted here is that C5L2, the second receptor of C5a, is also a functional receptor for ASP [ 11 ] . Recent reports suggest that C5L2 plays an active, positive role in infl ammatory responses [ 37 ] . Thus increases in C5a could translate into higher binding with C5L2, causing internalization, which might then lead to less C5L2 being available for ASP binding, also interfering with ASP function in this manner.
Direct co-culture of adipocytes with macrophages enhance ASP and C3 secretion
The present results demonstrate that numerous hormones, proand anti-infl ammatory factors and chemokines have varying eff ects on ASP production via eff ects on precursor C3 or C3 conversion to ASP. In obesity, immune cell infi ltration into adipose tissue results in increased secretion of many of these same factors [ 38 , 39 ] . While in the present study, macrophage-conditioned media alone had little eff ect on C3 or ASP, the co-culture of adipocytes with macrophages markedly altered ASP production. This suggests that there is a strong local crosstalk between these 2 types of cells. The process of macrophage infi ltration into adipose tissue could be mediated by the secretion of chemokines (such as TNF-α, MCP-1 and KC) by activated adipocytes, and at the same time the infi ltration of macrophages into adipose tissue would then be an important source of TNF-α, IL-6 and other infl ammatory factors [ 40 ] . Thus, direct co-culture with macrophages could lead to a vicious cycle of pro-inflammatory activation, which leads to synergistic eff ects on increased ASP and C3 production in adipocytes.
In light of these diff erential eff ects of adipokines, pro-and antiinfl ammatory factors and chemokines on ASP and C3, the relationship of ASP to various metabolic and hormonal dysfunctions is pertinent. Plasma ASP levels are increased in obesity, insulin resistance and related diseases such as cardiovascular disease, type 2 diabetes and polycystic ovary syndrome [ 33 , 41 -43 ] . Further, increased fasting plasma ASP is associated with a delay in postprandial triglyceride clearance in humans [ 8 ] . In vivo, this is also accompanied by reduced specifi c binding and response to ASP in cells from subjects with high ASP levels [ 42 ] . These increased ASP levels, accompanied with decreased receptor expression and ASP response, suggest that there exists an ASP resistance state. Further, ASP could be a novel pro-infl ammatory factor that stimulates secretion of certain cytokines and activates the NF-κB signalling pathway [ 44 ] . Thus, ASP is a biomarker for abnormal lipid metabolism and accumulation of fat tissue, where high ASP levels are associated with increased risk factors for metabolic abnormalities. In summary, various metabolic hormones and infl ammatory factors can aff ect ASP production through increased precursor C3 production and/or by changing the rate of C3 conversion to ASP. As an adipokine, ASP could constitute an additional link between adipose tissue and immune systems. Moreover, the crosstalk between adipocytes and macrophages enhances ASP and C3 production, further promoting infl ammation in adipose tissue, especially in states of obesity and its various associated complications.
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